As of 2026-09-15, the Intrinsic Value of Relmada Therapeutics Inc (RLMD) is -2.81 USD. This RLMD valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.44 USD, the upside of Relmada Therapeutics Inc is -163.21%.
Based on its market price of 4.44 USD and our intrinsic valuation, Relmada Therapeutics Inc (RLMD) is overvalued by 163.21%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.81 - -2.81 | -2.81 | -163.21% |
| P/E | (4.74) - (10.00) | (7.41) | -266.9% |
| DDM - Stable | (4.68) - (13.51) | (9.09) | -304.8% |
| DDM - Multi | (0.07) - (0.16) | (0.10) | -102.2% |
| Market Cap (mil) | 465.71 |
| Beta | 0.15 |
| Outstanding shares (mil) | 104.89 |
| Enterprise Value (mil) | 455.94 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.07% |
| Cost of Debt | 5.00% |
| WACC | 6.87% |